Wang Xiao, Ye Fuyu, Zhang Zhen, Zhang Qigui, Li Guanhua
Department of Psychological Assessment Room, Jiujiang Fifth People's Hospital, Jiujiang, Jiangxi Province, China.
Functional Inspection Room, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi Province, China.
Medicine (Baltimore). 2025 Jun 27;104(26):e42803. doi: 10.1097/MD.0000000000042803.
Bipolar disorder (BD) is a chronic mental health condition characterized by alternating manic and depressive episodes that significantly impact mood and cognitive function. Recent research has linked BD to neuroinflammation. Despite the availability of antipsychotics and mood stabilizers as standard treatments, their efficacy and side effects can vary, underscoring the need for more effective therapeutic strategies. This study aims to evaluate the combined effects of olanzapine and sodium valproate on clinical symptoms and inflammatory markers in patients with BD. A total of 80 BD patients from the Fifth People's Hospital of Jiujiang, treated between April 2022 and April 2024, were enrolled in the study. They were divided into 2 groups: the control group, which received olanzapine monotherapy, and the observation group, which received a combination of olanzapine and sodium valproate. After 8 weeks of treatment, clinical efficacy was assessed using the Bech-Rafaelsen Mania scale and the Hamilton depression scale. Serum inflammatory markers, including interleukin-1, interleukin-10, and tumor necrosis factor-alpha, were measured along with neuroendocrine function indicators (thyroid hormone, cortisol, thyroid-stimulating hormone, and adrenocorticotropic hormone). Cognitive function was evaluated using computerized assessments, and adverse events were monitored and recorded. The observation group exhibited significantly lower Bech-Rafaelsen Mania scale and Hamilton depression scale scores, as well as reduced interleukin-1 and tumor necrosis factor-alpha levels compared to the control group. Both groups showed decreased levels of serum thyroid hormone, cortisol, and adrenocorticotropic hormone, along with increased thyroid-stimulating hormone levels after treatment, with more pronounced changes observed in the observation group (P < .01). Additionally, cognitive function scores were significantly higher in the observation group (P < .05), and the incidence of adverse events was lower (15.00% vs 22.50%, χ² = 0.38, P < .01). The combination of olanzapine and sodium valproate leads to significant improvements in clinical symptoms, reduces inflammatory markers, enhances cognitive function, and demonstrates greater safety compared to olanzapine monotherapy. This combination therapy offers a promising treatment approach for managing BD.
双相情感障碍（BD）是一种慢性心理健康状况，其特征为躁狂和抑郁发作交替出现，对情绪和认知功能有显著影响。最近的研究已将双相情感障碍与神经炎症联系起来。尽管有抗精神病药物和心境稳定剂作为标准治疗方法，但它们的疗效和副作用可能各不相同，这突出表明需要更有效的治疗策略。本研究旨在评估奥氮平和丙戊酸钠联合使用对双相情感障碍患者临床症状和炎症标志物的综合影响。共有80名来自九江第五人民医院的双相情感障碍患者参与了该研究，这些患者在2022年4月至2024年4月期间接受治疗。他们被分为两组：对照组接受奥氮平单药治疗，观察组接受奥氮平和丙戊酸钠联合治疗。治疗8周后，使用Bech-Rafaelsen躁狂量表和汉密尔顿抑郁量表评估临床疗效。测量血清炎症标志物，包括白细胞介素-1、白细胞介素-10和肿瘤坏死因子-α，以及神经内分泌功能指标（甲状腺激素、皮质醇、促甲状腺激素和促肾上腺皮质激素）。使用计算机化评估来评估认知功能，并监测和记录不良事件。与对照组相比，观察组的Bech-Rafaelsen躁狂量表和汉密尔顿抑郁量表得分显著更低，白细胞介素-1和肿瘤坏死因子-α水平也有所降低。两组治疗后血清甲状腺激素、皮质醇和促肾上腺皮质激素水平均下降，促甲状腺激素水平升高，观察组的变化更为明显（P < 0.01）。此外，观察组的认知功能得分显著更高（P < 0.05），不良事件发生率更低（15.00% 对 22.50%，χ² = 0.38，P < 0.01）。与奥氮平单药治疗相比，奥氮平和丙戊酸钠联合使用可显著改善临床症状，降低炎症标志物水平，增强认知功能，并显示出更高的安全性。这种联合治疗为双相情感障碍的管理提供了一种有前景的治疗方法。
